Feedback

miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease

Affiliation
Department of Quality Assurance ,SVKM’s Dr. Bhanuben Nanavati College of Pharmacy ,Mumbai ,India
Suvarna, Vasanti;
Affiliation
Department of Quality Assurance ,SVKM’s Dr. Bhanuben Nanavati College of Pharmacy ,Mumbai ,India
Deshmukh, Kajal;
Affiliation
Department of Pharmacy ,Koneru Lakshmaiah Education Foundation ,Vaddeswaram ,AP ,India
Murahari, Manikanta

α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lysosomal dysregulation, mitochondrial disruption, synaptic dysfunction, and oxidative stress. Moreover, the alpha-synuclein aggregation has been associated with the development of several neurodegenerative conditions such as various forms of Parkinson’s disease. The recent discovery in oligonucleotide chemistry has developed potential alpha-synuclein targeting molecules for the treatment of neurodegenerative diseases. The present review article focuses on recent advances in the applications of oligonucleotides acting via alpha-synuclein targeting mechanisms and their implication in combating Parkinson’s disease. Moreover, the article emphasizes the potential of miRNAs, and antisense oligonucleotides and the challenges associated with their use in the therapeutical management of Parkinson’s disease.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Suvarna, Deshmukh and Murahari.

Use and reproduction: